Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer – predictors of response and impact of previous radiotherapy

References

• SEER NCI. Cancer stat facts: lung and bronchus cancer. USA: National Cancer Institute. Bethesda (MD): SEER; 2019. Available from: https://seer.cancer.gov/statfacts/html/lungb.html
   Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, KEYNOTE-001 Investigators, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Borghaei H, Ramalingam SS, et al. Abstract CT195: long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): impact of early disease control and response. Cancer Res. 2019;79(13):CT195.
   Web of Science ®Google Scholar
• Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the Phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518–2527.
   PubMed Web of Science ®Google Scholar
• von Pawel J, Bordoni R, Satouchi M, et al. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: results from the randomised phase III OAK study. Eur J Cancer. 2019;107:124–132.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
   PubMed Web of Science ®Google Scholar
• Ahmadzada T, Kao S, Reid G, et al. An update on predictive biomarkers for treatment selection in non-small cell lung cancer. J Clin Med. 2018;7(6):153.
   PubMed Web of Science ®Google Scholar
• Remon J, Passiglia F, Ahn MJ, et al. Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations. J Thorac Oncol. 2020;15(6):914–947.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2969–2979.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Reynolds C, Waterhouse D, et al. Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation - positive advanced non-small cell lung cancer (CheckMate 370). J Thorac Oncol. 2018;13(5):682–688.
   PubMed Web of Science ®Google Scholar
• Ngwa W, Irabor OC, Schoenfeld JD, et al. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18(5):313–322.
   PubMed Web of Science ®Google Scholar
• Lin AJ, Roach M, Bradley J, et al. Combining stereotactic body radiation therapy with immunotherapy: current data and future directions. Transl Lung Cancer Res. 2019;8(1):107–115.
   PubMed Web of Science ®Google Scholar
• D’Andrea MA, Reddy GK. Systemic immunostimulatory effects of radiation therapy improves the outcomes of patients with advanced NSCLC receiving immunotherapy. Am J Clin Oncol. 2020;43(3):218–228.
   PubMed Web of Science ®Google Scholar
• Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1–2):48–61.
   PubMed Web of Science ®Google Scholar
• Andersen PK, Geskus RB, de Witte T, et al. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol. 2012;41(3):861–870.
   PubMed Web of Science ®Google Scholar
• Tan KS, Eguchi T, Adusumilli PS. Competing risks and cancer-specific mortality: why it matters. Oncotarget. 2018;9(7):7272–7273.
   PubMedGoogle Scholar
• Stensrud MJ, Hernan MA. Why test for proportional hazards? JAMA. 2020;323(14):1401.
   PubMed Web of Science ®Google Scholar
• Gu XB, Tian T, Tian XJ, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep. 2015;5:12493.
   PubMed Web of Science ®Google Scholar
• Diem S, Schmid S, Krapf M, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181.
   PubMed Web of Science ®Google Scholar
• Oya Y, Yoshida T, Kuroda H, et al. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. Oncotarget. 2017;8(61):103117–103128.
   PubMedGoogle Scholar
• Jing X, Huang C, Zhou H, et al. Association between serum C-reactive protein value and prognosis of patients with non-small cell lung cancer: a meta-analysis. Int J Clin Exp Med. 2015;8(7):10633–10639.
   PubMed Web of Science ®Google Scholar
• Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5(9):1276–1282.
   PubMed Web of Science ®Google Scholar
• Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903.
   PubMed Web of Science ®Google Scholar
• Fares CM, Allen EMV, Drake CG, et al. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book. 2019;39:147–164.
   PubMedGoogle Scholar
• Monjazeb AM, Schalper KA, Villarroel-Espindola F, et al. Effects of radiation on the tumor microenvironment. Semin Radiat Oncol. 2020;30(2):145–157.
   PubMed Web of Science ®Google Scholar
• Arnold KM, Flynn NJ, Raben A, et al. The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules. Cancer Growth Metastasis. 2018;11:1179064418761639.
   Web of Science ®Google Scholar
• Freidlin B, Korn EL. Methods for accommodating nonproportional hazards in clinical trials: ready for the primary analysis? J Clin Oncol. 2019;37(35):3455–3459.
   PubMed Web of Science ®Google Scholar
• Tian L, Jin H, Uno H, et al. On the empirical choice of the time window for restricted mean survival time. Biometrics. 2020. DOI:10.1111/biom.13237
   Web of Science ®Google Scholar
• Bellera CA, MacGrogan G, Debled M, et al. Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer. BMC Med Res Methodol. 2010;10(1):20.
   PubMedGoogle Scholar
• Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845–1851.
   PubMed Web of Science ®Google Scholar
• Yang H, Jin T, Li M, et al. Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges. Precision Clin Med. 2019;2(1):57–70.
   PubMedGoogle Scholar